The Global Cancer Drug Market size valued at USD 112.73 billion in 2019, and is predicted to reach USD 215.11 billion by 2030, with a CAGR of 5.9%, from 2020-2030.
Cancer is a chronic disease that tends to initiate abnormal growth of cells, leading to formation of tumors that have tendency to propagate throughout the lymphatic system, blood, and tissues in the human body. Conversely, benign tumors are non-cancerous tumors. There are different types of cancers like lung cancer, stomach cancer, breast cancer, prostate cancer, liver cancer, esophagus cancer, cervical cancer, renal cancer, bladder cancer, and others. Cancer can be diagnosed with the help of various clinical investigations such as CT scans, blood test, biopsy, and others diagnostic options. In early stages of cancer, chemotherapy is used as first-line treatment, and for chronic cancer diseases targeted therapy, immunotherapy as well as a combination of different therapies is used as treatment options.
Access Full Description of this report at:-
Top Companies: Astellas Pharma Inc., AbbVie Inc., Bristol-Myers Squibb Company, AstraZeneca PLC, f. Hoffmann-La Roche ltd., Celgene Corporation, Merck & Co., Inc., Johnson & Johnson (Janssen Global Services, LLC,), Pfizer Inc., and Novartis AGand others.
The global cancer drug market share has been analyzed based on drug class, indication and geography. Based on drug class, the cancer drug market is segmented into Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), and Hormonal Therapy. Based on indication, the cancer drug market is divided into Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer, and Other. Geographic breakdown and analysis of each of the previously mentioned segments include regions comprising North America, Europe, Asia-Pacific, and RoW.
Request sample copy of this report at:-
North America dominated the global cancer drug market in the past and is expected to maintain its dominance throughout the forecast period. This is attributed to well-established healthcare infrastructure, presence of specialized medical practitioners & surgeons, advancements in product technologies, increasing inclination towards sedentary lifestyles and easy access to premium chemotherapy treatments in this region. Asia Pacific region is expected to witness a substantial growth in the global cancer drug market throughout the forecast period, witnessing the highest CAGR values. Factors responsible for boosting the cancer drug market growth in this region are, improving healthcare infrastructures, growing consumer awareness about different cancer treatment options, increasing investment in R&D activities, raise in per-capita disposable incomes, as well as untapped market opportunities offered by the emerging economies present in this region.
About Next Move Strategy Consulting:
Next Move Strategy Consulting is an independent and trusted third-platform market intelligence provider, committed to deliver high quality, market research reports that help multinational companies to triumph over their competitions and increase industry footprint by capturing greater market share. Our research model is a unique collaboration of primary research, secondary research, data mining and data analytics.
We have been servicing over 1000 customers globally that includes 90% of the Fortune 500 companies over a decade. Our analysts are constantly tracking various high growth markets and identifying hidden opportunities in each sector or the industry. We provide one of the industry’s best quality syndicate as well as custom research reports across 10 different industry verticals. We are committed to deliver high quality research solutions in accordance to your business needs. Our industry standard delivery solution that ranges from the pre consultation to after-sales services, provide an excellent client experience and ensure right strategic decision making for businesses.
For more insights, please visit,https://www.nextmsc.com